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This study investigated the role of exogenous α-lipoic acid (ALA) in the inflammation caused by zymosan 
application. Seventy-two adult male white mice were divided into twelve groups: three control groups, 
three Zymosan groups, three ALA groups and three groups being the combination of Zymosan and ALA. 
In the experimental groups, the animals were decapitated after 3, 6 and 24 hours after the injection. The 
activity of superoxide dismutase (SOD), catalase (CAT) and glutathione peroxidase (GSH-Px) were 
determined in the brain, liver and kidneys of the mice. After the injection of Zymosan, it was found that 
the activity of SOD, CAT and GSH-Px in the brain, liver and kidneys of mice was significantly lower in 
all time periods. The administration of ALA resulted in an opposite effect, namely, it increased the activ-
ity of the enzymes studied in the selected organs of mice. The Zymosan and ALA combination signifi-
cantly inhibited the decrease in the activity of the enzymes compared with the values obtained in the 
groups of animals which received Zymosan only. The results of our study, using the Zymosan-induced 
inflammation, clearly indicate that ALA is an anti-inflammatory agent.
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INTRODUCTION
Zymosan is a substance derived from the cell wall of the yeast Saccharomyces cerevi-
siae and consists of protein-carbohydrate complexes. When injected into animals it 
induces inflammation by stimulating a wide range of inflammatory mediators. These 
induce activated components of the complement system, prostaglandins and leukot-
* Corresponding author; e-mail address: z.goc@vp.pl
Abbreviations: ALA = α-lipoic acid, ANOVA = analysis of variance, BSA = bovine serum albumin, 
b.w. = body weight, CAT = catalase, DHLA = dihydrolipoic acid, EDTA = ethylenediaminetetra acetic 
acid disodium salt, GSH = reduced glutathione, GSH-Px = glutathione peroxidase, H2O2 = hydrogen 
peroxide, •HO = hydroxyl radical, HOCl = hypochlorous acid, i.p. = intraperitoneal injection, 
K2HPO4 = dipotassium hydrogen phosphate, KH2PO4 = potassium dihydrogen phosphate, LA = DL-α-
lipoic acid, NO = nitric oxide, ONOO– = peroxynitrite, PUFA = polyunsaturated fatty acids, RNS = reac-
tive nitrogen species, ROS = reactive oxygen species, 1O2 = singled oxygen, SOD = superoxide dis-
mutase
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rienes, platelet aggregation factor, reactive oxygen species (ROS) and lysosomal 
enzymes [19, 39].
Overproduction of free radicals leads to oxidative stress which may lead to the 
destruction of healthy tissue. Indeed, at high concentrations and with continued expo-
sure, ROS can damage all types of biomolecules including DNA, lipids, carbohy-
drates and proteins. This harmful effect is counteracted by the antioxidant action of 
both enzymatic, as well as, non-enzymatic antioxidants [43].
α-Lipoic acid (ALA; 5-(1,2-dithiolan-3-yl) pentanoic acid), is a sulfur-containing 
fatty acid. It is found naturally in the human body at very low concentrations, primar-
ily in the mitochondria where it helps to generate the energy that keeps us alive and 
functioning. ALA is a biogenic antioxidant which physiologically acts as a coenzyme 
in the oxidative decarboxylation of α-keto acids, such as from pyruvate into acetyl-
CoA [42]. The cyclic disulfide ALA is a potent free-radical scavenger that is absorbed 
from the diet, transported into cells, and reduced to its open chain form dihydrolipoic 
acid (DHLA), which has even greater antioxidant activity than ALA. Both forms can 
be quickly converted into each other by redox reactions [4]. 
ALA has scavenge numerous reactive oxygen and nitrogen species such as hydrox-
yl radical (•HO), hypochlorous acid (HOCl), peroxynitrite (ONOO–) and singled 
oxygen (1O2) [33]. In addition, ALA supplement has been shown to reduce cellular 
injury caused by antioxidant deficiency. ALA supplementation has been demonstrated 
to prevent symptoms of vitamin E deficiency in mice [36], as well as, to inhibit neu-
rotoxicity caused by GSH depletion in neuronal cells [17]. Consequently, many bio-
logical effects of ALA supplementation can be attributed to the antioxidant properties 
of ALA [30]. 
Unlike to other antioxidants, that function only in water or fatty tissues, ALA is 
unusual because it can work in both water and fat. This gives α-lipoic acid an unusu-
ally broad spectrum of antioxidant action [22]. ALA has been termed the ‘ideal’ 
antioxidant, and it has been used in treating diseases in which oxidative stress plays 
a major role [27]. 
To confirm this suggestion, we decided to investigate the effect of single dose of 
ALA on the activity of superoxide dismutase (SOD), catalase (CAT) and glutathione 
peroxidase (GSH-Px) in the brain, liver and kidneys of mice that had previously been 
given zymosan. SOD, CAT and GSH-Px are vital components of the antioxidative 
barrier in animal cells. It is suggested more often now that the effectiveness of the 
protection of cells against the oxidative stress caused by the inflammation process 
depends on the activity of those enzymes.
MATERIALS AND METHODS
Seventy-two adult (4 month-old) male white mice, line Swiss, of the average body 
weight 27 grams, were used. All animals were obtained from the Experimental 
Research Laboratory of the Institute of Biology, Pedagogical University of Cracow 
and were housed in a well-ventilated experimental animal room under controlled 
260 Zofia Goc et al.
Acta Biologica Hungarica 66, 2015
conditions on a 12 h light/12 h dark cycle at 20 °C to 22 °C, relative humidity 
55% ± 5%, with free access to standard pellet diet (LMS, laboratory producing fodder 
for experimental animals, Motycz near Lublin) and water ad libitum. 
The study comprised one control series and three series of experiments. Each 
series consisted of three groups of six animals each. Mice of the control groups 
received intraperitoneal (i.p.) 0.3 ml of 0.9% NaCl solution (Polfa, Poland) at 8.00 
a.m. The experimental animals of the first series received a single injection (i.p.) of 
Zymosan (Sigma, St. Louis, MO) at the dose of 100 mg/kg body weight (b.w.) dis-
solved in 0.9% NaCl solution at the same time of the day, i.e. at 8.00 a.m. The 
Zymosan doses were established according to other authors’ suggestions [35, 44]. 
Mice of the second experimental series received a single injection (i.p.) of α-lipoic 
acid (ALA) (Sigma, St. Louis, MO) at the dose of 100 mg/kg b.w. dissolved in olive 
oil at 8.00 a.m. The doses were established according to other authors’ suggestions 
[32, 39]. The experimental animals of the third series received simultaneously the 
injections (i.p.) of Zymosan at the dose of 100 mg/kg b.w. and ALA at the dose 100 
mg/kg b.w. at the same time of the day, i.e. at 8.00 a.m.
Both control and experimental animals were decapitated 3, 6, and 24 hours after 
the administration of 0.9% NaCl, Zymosan, ALA, or Zymosan and ALA combina-
tion. Before decapitation they were anesthetized by intramuscular administration of 
vetbutale (Biowet, Poland) at the dose of 35 mg/kg b.w. diluted with 0.9% NaCl solu-
tion. The organs under investigation, that is the brain, liver and kidneys, were quick-
ly removed.
The excised organs were homogenized in cooled to 4 °C 50 mM phosphate buffer, 
containing K2HPO4 (dipotassium hydrogen phosphate) + KH2PO4 (potassium dihy-
drogen phosphate) + 0.1 mM EDTA (ethylenediaminetetra acetic acid disodium salt) 
(pH = 7.0) + 0.1% BSA (bovine serum albumin) and then centrifuged. The obtained 
supernatants (tissue extracts) of brain, liver and kidneys were used for further inves-
tigations. 
SOD activity was determined according to the method of Rice-Evans et al. [37]; 
CAT with Aebi spectrophotometry method [1]; GSH-Px with modified method of 
Lück [29]. Total protein concentration in the supernatants of homogenates of brain, 
liver and kidneys was determined by the method of Bradford [5] using bovine serum 
albumin as standard. The measurements of absorbance for all the analyses of the 
enzymes and proteins were carried with Beckman DU-650 spectrophotometer. The 
activity of the studied antioxidative enzymes in tissue extracts was calculated in 
U/mg of protein.
The obtained results of SOD, CAT and GSH-Px activity in the brain, liver and 
kidneys were used to calculate the arithmetic means and standard deviations. The 
results were subjected to statistical verification using test “t” Student-Gosset. 
Differences were considered statistically significant at p < 0.001. The percentage 
changes in the activity of tested enzymes in the experimental groups compared to the 
corresponding control group were calculated. In order to estimate the obtained 
changes in the activity of SOD, CAT and GSH-Px in the studied organs, in all the 
analyzed periods of time for each experimental group, the ANOVA variance analysis 
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test was performed. Differences were considered statistically significant at p < 0.05, 
p < 0.01 and p < 0.001. All analyses were performed using the computer program 
STATISTICA 9 (StatSoft, Cracow, Poland).
RESULTS
The results concerning the activity of the antioxidant enzymes (SOD, CAT and GSH-
Px) in the brain, liver and kidneys of the control and experimental animals are shown 
in Tables 1, 2. In comparison with the control values, the administration of Zymosan 
caused a statistically significant decrease in the activity of SOD in the examined 
organs in all the analyzed periods of time, i.e. 3, 6 and 24 hours after the injection. 
 
Table 1
The activities of superoxide dismutase (SOD), catalase (CAT) and glutathione peroxidase (GSH-Px)  
in brain of 4-month-old male mice, line Swiss, 3, 6 and 24 hours after the intraperitoneal (i.p.) 
administration of Zymosan at the dose of 100 mg/kg body weight (b.w.), α-lipoic acide (ALA) 
at dose of 100 mg/kg (b.w.) and simultaneously (i.p.) of Zymosan at the dose of 100 mg/kg (b.w.) 
and ALA at the dose 100 mg/kg (b.w.)
Experimental groups
The activity of antioxidant enzymes – SOD, CAT and GSH-Px in U/mg protein
BRAIN
SOD CAT GSH-Px
Control I
Zymosan after 3 h
test “t”
α-lipoic acid (ALA) after 3 h
test “t”
Zymosan + ALA after 3 h
test “t”
8.083±0.138
5.700±0.110
33.017*
8.365±0.123
3.722**
7.205±0.117
11.880*
0.226±0.012
0.134±0.006
16.797*
0.290±0.013
9.066*
0.185±0.010
6.329*
0.028±0.003
0.0135±0.001
12.462*
0.039±0.002
6.873*
0.021±0.002
5.412*
Control II
Zymosan after 6 h
test “t”
α-lipoic acid (ALA) after 6 h
test “t”
Zymosan + ALA after 6 h
test “t”
7.997±0.159
3.728±0.118
52.645*
8.157±0.094
2.112
5.828±0.087
29.174*
0.236±0.018
0.140±0.007
11.887*
0.370±0.031
9.106*
0.198±0.015
3.853**
0.027±0.004
0.012±0.001
8.806*
0.030±0.002
1.486
0.018±0.003
4.135**
Control III
Zymosan after 24 h
test “t”
α-lipoic acid (ALA) after 24 h
test “t”
Zymosan + ALA after 24 h
test “t”
8.014±0.147
3.243±0.094
66.748*
8.089±0.103
1.022
5.938±0.088
29.554*
0.218±0.019
0.170±0.011
5.189*
0.246±0.020
2.537***
0.206±0.015
1.216
0.029±0.004
0.020±0.003
4.326**
0.028±0.002
0.104
0.024±0.001
2.474***
  *Statistically significant at p < 0.001.
 **Statistically significant at p < 0.01.
***Statistically significant at p < 0.05.
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The highest decrease was observed always after 24 h since the beginning of the 
experiment, in the brain by 59.53% (Table 1), liver by 55.47% and kidneys by 
53.33% (Table 2). The variance analysis test (ANOVA) showed that these changes in 
the activity of SOD were statistically significant at p < 0.001 in the brain (F(2,15) = 
867.767), liver (F(2,15) = 318.319) and kidneys (F(2,15) = 248.651).
The injection of Zymosan also resulted in a statistically significant decrease in the 
activity of CAT in all investigated organs in all the analyzed periods of time. The 
highest decrease in the activity of CAT has been observed in the brain after 6 hours 
by 40.76% (Table 1), while in the liver and kidneys, after 24 hours by 25.54% and 
40.24%, respectively (Table 2). The variance analysis test (ANOVA) showed that the 
changes in the activity of CAT were statistically significant at p < 0.001 only in the 
brain (F(2,15) = 30.057) and kidneys (F(2,15) = 19.893).
We also observed a statistically significant decrease in the GSH-Px activity in all the 
studied groups after the Zymosan treatment. The highest percentage of changes in the 
activity of GSH-Px was observed in the brain after 3 hours (decrease by 57.78%) 
(Table 1) and in the liver and kidneys after 6 hours by 62.19% and 58.80%, respec-
tively (Table 2). The variance analysis test (ANOVA) showed that these changes in the 
activity of GSH-Px were statistically significant in the brain (F(2,15) = 29.011, 
p < 0.001), liver (F(2,15) = 218.230, p < 0.001) and kidneys (F(2,15) = 7.808, p < 0.01). 
The administration of ALA caused a statistically significant increase in the activity 
of SOD in the brain only after 3 hours, 3.53% (Table 1). In the liver, we estimated a 
statistically significant increase in the activity of this enzyme after 3 and 6 hours 
(13.26% and 19.07%), whereas in the kidney a significant increase was observed dur-
ing all the analyzed periods of time, namely, 21.74% after 3 hours, 40.37% after 6 
hours and 14.25% after 24 hours (Table 2). ANOVA showed that these changes in the 
activity of SOD are statistically significant at p < 0.01 in the brain (F(2,15) = 10,678), 
and at p < 0.001 liver (F(2,15) = 57.549) and kidneys (F(2,15) = 94.308).
Furthermore, ALA induced a significant increase in the activity of CAT in the brain 
by 28.32% after 3 hours and 56.77% after 6 hours and 12.84% after 24 h since the 
beginning of the experiment (Table 1). Whilst, in the liver, a significant increase in 
the activity of this enzyme was found after 6 (64.77%) and 24 hours (12.90%) (Table 
2). In the case of kidneys a statistically significant increase in the activity of CAT was 
found only after 3 hours (24.02%) (Table 2). ANOVA showed that the detected 
changes were statistically significant in the brain (F(2,15) = 46,868), liver (F(2,15) = 
143.079) and kidneys (F(2,15) = 17.670) at p < 0.001.
Meanwhile, the administration of ALA caused a significant increase in the activity 
of GSH-Px in the brain only after 3 hours (Table 1), in the kidneys after 3 and 6 hours, 
whereas in the liver in all time partitions (Table 2). The highest percentage of chang-
es in the analyzed organs was always observed after 3 hours since the beginning of 
the experiment, i.e. brain increase by 38.57%, liver – 37.31% and kidneys – 53.84%. 
ANOVA showed that these differences in the activity of GSH-Px were statistically 
significant at p < 0.001 in the brain (F(2,15) = 38.257), liver (F(2,15) = 35.478) and 
kidneys (F(2,15) = 77.922).
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The simultaneous injection i.p. of Zymosan and ALA in mice caused a significant 
decrease is the activity of SOD in the brain and liver after 3, 6 and 24 hours after the 
injection, as compared to the saline-treated mice. The highest decrease in the brain by 
27.13% was observed after 6 hours (Table 1) and in the case of the liver, it equalled 
30.72% after 3 hours (Table 2). A statistically significant decrease in SOD activity 
was observed in the kidneys after 3 (26.38%) and 24 hours (12.64%) (Table 2). The 
variance analysis test (ANOVA) showed that these changes in the activity of SOD are 
statistically significant at p < 0.001 in the brain (F(2,15) = 359.485), liver (F(2,15 = 
235.353) and kidneys (F(2,15) = 337.468).
The administration of Zymosan and ALA caused a significant decrease in the activ-
ity of CAT in the brain only after 3 and 6 hours by 18.14% and 16.1%, respectively 
(Table 1). In the liver, statistically significant changes of CAT were detected in all 
bands, but the highest decrease was recorded after 24 hours (13.71%) (Table 2). In 
the case of kidneys a statistically significant decrease in the activity of CAT was 
found exclusively after 6 and 24 hours (24.25% and 18.78%, respectively) (Table 2). 
The variance analysis test (ANOVA) showed that these changes in the activity of CAT 
in the analyzed organs were statistically significant at p < 0.05, only in the kidneys 
(F(2,15) = 6.067).
Furthermore, the injection of Zymosan and ALA caused a significant decrease in 
the activity of GSH-Px in the brain and liver in all the analyzed periods. After 6 hours 
we observed the highest decrease of this enzyme in the brain (32.71%) (Table 1), as 
well as, in the liver (30.35%) (Table 2). In the case of kidneys, a statistically signifi-
cant decrease of GSH-Px was found after 3 hours (25.64%) and 6 hours (15.09%). 
(Table 2). The variance analysis test (ANOVA) showed that these changes in the 
activity of GSH-Px were statistically significant in the brain (F(2,15) = 8.565, 
p < 0.01), liver (F(2,15) = 39.440, p < 0.001) and kidneys (F(2,15) = 23.009, p < 0.001).
DISCUSSION
In the present experiments, the physiological alterations in the examined organs of 
mice after Zymosan and ALA administration have been shown. These changes were 
manifested in various activities of SOD, CAT and GSH-Px after the administration of 
Zymosan, ALA or Zymosan and ALA in the brain, liver and kidneys.
Antioxidant enzymes play an important role in the protection from oxidative 
injury to the body. One of the therapeutic approaches by which these disorders can be 
prevented, is the increase of the levels of SOD, CAT and, GSH-Px in the body by 
interventions which may include the intake increases of dietary supplements rich in 
antioxidants/antioxidant enzymes. Altered SOD levels and chronic inflammation 
have been associated with neurodegenerative diseases [26], metabolic diseases, and 
liver diseases [23]. SOD mainly act by quenching the superoxide (O2•–), CAT by 
catalyzing the decomposition of H2O2 to water and oxygen. GSH-Px is a selenium 
containing enzyme which catalyses the reduction of H2O2 and lipid hydroperoxide, 
generated during lipid peroxidation, to water, using reduced glutathione (GSH) as 
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substrate [25, 28]. The decreased levels of the antioxidant enzymes such as SOD CAT 
and GSH-Px could reflect mitochondrial dysfunction [38]. 
The intraperitoneal administration of Zymosan in mice leads to several illnesses in 
experimental animals, characterized by a systemic toxicity and significant loss of 
body weight. Also, Zymosan increased the production of pro-inflammatory cytokines 
and mediators, causing a generalized dysfunction of liver, lung and kidneys in female 
mice [11]. Zymosan is not degradable and its application to animals represents a new 
experimental shock model by acute peritonitis induction, severe hypotension, and 
signs of systemic illness [20]. It is a well-known fact that chronic inflammatory dis-
eases are associated with enhanced ROS and reactive nitrogen species (RNS) produc-
tion exemplified by elevated levels of NO and H2O2 in the site of inflammation [3, 
13]. These oxidants can be generated by enzymes abundant not only in inflammatory 
cells but also in non-inflammatory cells [21].
The brain is particularly sensitive to oxidative damage. This is due to the consump-
tion of large amounts of oxygen, a high concentration of unsaturated fatty acids and 
a relatively high concentration of heavy metal ions. Furthermore, the brain tissue 
contained a small amount of substances with antioxidant properties [7]. So, it is more 
susceptible to oxidative damage than other tissues [10, 15]. In the experiment, the 
supply – of Zymosan resulted in a clear decrease in the activity of SOD, CAT and 
GSH-Px in the brain. Similar changes in these enzymes activity in the brain of mice 
after the lower dose of Zymosan (40 mg/kg b.w.) injection were found in earlier 
experiment [43]. In the same experiment, the authors observed a significant decrease 
in the activity of those enzymes in other organs, i.e. liver and kidney what confirms 
our results. The liver is the main detoxifying organ in the body, and it shows high 
metabolic rate and it is subjected to oxidative stress. Similarly, the abundance of 
polyunsaturated fatty acids (PUFA) makes the kidney an organ particularly vulnera-
ble to ROS attack [24]. 
ALA feeding was shown to increase ambulant activity, mitochondrial respiration, 
and carnitine acetyltransferase activity, as well as, to decrease oxidative stress in old 
rats, increase GSH levels in aged animals what suggesting that ALA feeding increas-
es the redox potential of cells and mitochondria [16]. Akpinar et al. [2] investigated 
the effect of ALA on lipid peroxidation, nitric oxide production and antioxidant sys-
tems in rats exposed to chronic restraint stress. ALA increased the activities of SOD, 
GSH-Px and CAT in the non-stressed and stressed rats in relation to their correspond-
ing groups. From the results they obtained, it could be concluded that this compound 
has an excellent antioxidant activity. This is also confirmed by Chen et al. [8] who 
observed significantly increased SOD and GSH-Px activity in serum, liver and breast 
muscles in chickens fed with ALA. Furthermore, the concentration of glutathione 
(GSH) in liver, and α-tocopherol content in leg muscle was significantly higher as 
compared to the control. In accordance with those studies, we also observed a statis-
tically significant increase in the activity of CAT, SOD, and GSH-Px after ALA treat-
ment at different time intervals for individual organs, which may be the result of their 
physiological functions. 
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SOD and GSH-Px are parts of the enzymatic antioxidant defense systems against 
ROS. SOD acts as the first line of defense against oxyradicals in cells by catalyzing 
the dismutation of endogenous cytotoxic superoxide radicals to H2O2 following that 
GSH-Px detoxify hydrogen peroxide produced [31]. Additionally, earlier studies [18, 
41] have suggested that ALA can reduce oxidized GSH and increase the GSH status, 
which in turn exhibits increased free radical scavenging property. Besides, the 
increased intracellular GSH content might activate the GSH dependent enzyme such 
as GSH-Px, thus preventing the accumulation of hydrogen peroxide. When GSH-Px 
succeeded eliminating H2O2 from the cell, the fallen H2O2 has been shown to cause 
activation of SOD [40]. The increase in the activities of these enzymes could indicate 
the positive effects of ALA on this finely balanced antioxidant system. 
It should be emphasized that several other studies have also provided evidence for 
protective effects of ALA supplementation against oxidative tissue damage in various 
animal models of ischemia – reperfusion, hepatic disorders, and diabetes [6, 12]. 
According to Feng et al. [14] α-lipoic acid has effects on the kidneys of diabetic rats, 
increasing the levels of GSH, SOD, vitamins E, and C in ALA-treated group, com-
pared to the diabetic group. Further evidence for in vivo efficiency of ALA in inflam-
matory diseases is given by the fact that ALA inhibits airway inflammation in a 
mouse model of asthma. ALA also significantly reduced inflammatory markers, an 
effect most likely by attenuated NF-kB DNA-binding activity [9].
In our study, the administration of ALA and then Zymosan significantly reduced 
the loss of activity of SOD, CAT and GSH-Px, as compared to the mice treated with 
Zymosan only in relation to the control groups in all organs. The results have demon-
strated an anti-inflammatory activity of ALA in mice, which had been confirmed by 
Zygmunt et al. [45]. ALA has decreased the count of neutrophils in a model of 
Zymosan-induced peritonitis and significantly inhibited early vascular permeability 
in the Zymosan-treated group as compared to the control group. ALA serves as a 
sulfane sulfur acceptor and releases it in the form of hydrogen sulfide (H2S), which is 
probably responsible for its anti-inflammatory activity. Hydrogen sulfide inhibits the 
release of pro-inflammatory cytokines and NO•. These effects depend on the dose and 
rate of hydrogen sulfide release at different stages of infection. The most capable way 
affects low concentrations of H2S being released slowly during a long time. It is pos-
sible that in this way hydrogen sulfide is released, which would explain the anti-
inflammatory action of ALA. 
The results obtained from our experiments and literature data suggest that the ALA 
can be considered as “ideal antioxidant” with abilities to scavenge reactive species 
and reset antioxidant levels. ALA influences endogenous cellular antioxidant levels 
and probably reduces pro-inflammatory mechanisms.
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